Background: The primary goals in conducting clinical trials of treatments for alcohol use disorders (AUDs) are to identify efficacious treatments and determine which treatments are most efficacious for which patients. Accurate reporting of study design features and results is imperative to enable readers of research reports to evaluate to what extent a study has achieved these goals. Guidance on quality of clinical trial reporting has evolved substantially over the past 2 decades, primarily through the publication and widespread adoption of the Consolidated Standards of Reporting Trials statement. However, there is room to improve the adoption of those standards in reporting the design and findings of treatment trials for AUD.
T HE ULTIMATE GOAL of most randomized clinical trials (RCTs) is to identify efficacious treatments for a sample of individuals. The accurate reporting of trial design features, sample characteristics, statistical methods, and results is imperative for the readers to determine whether a given study has achieved this goal. In addition, clearly reported information is needed to generate useful syntheses of research findings. Over the past few decades, several attempts have been made to improve the quality of reporting of RCTs, with the primary goal being increased transparency and confidence in the reliability and validity of trial findings. Importantly, many aspects of clinical trial design (e.g., eligibility criteria [Humphreys et al., 2008] , randomization allocation) and analysis (e.g., procedures for handling missing data), if not well chosen and well implemented, can introduce systematic biases into the estimates of treatment efficacy (Witkiewitz et al., 2015) . Reporting of design features and analysis methods that may impact estimates of treatment efficacy is particularly important in RCTs evaluating treatments for alcohol use disorders (AUDs), given that relatively few efficacious treatments exist (Jonas et al., 2014; National Institute for Health and Care Excellence, 2011; Zindel and Kranzler, 2014) . Witkiewitz and colleagues (2015) provide an overview of recommendations for the design and analysis of alcohol treatment studies, including (i) considerations for recruitment, randomization, and retention; (ii) the selection of measures to assess outcomes, intervention fidelity, and adherence; (iii) timing of assessments and the study of mechanisms of behavior change; and (iv) statistical methods used to assess treatment efficacy.
Here, we provide a brief review of the Consolidated Standards of Reporting Trials (CONSORT; Altman et al., 2001; Begg et al., 1996; Schulz et al., 2010) . We also discuss empirical findings that guide recommendations to improve the quality of reporting of findings from AUD treatment trials. To reduce overlap with prior reviews of reporting standards, we focus on the reporting of study features in 4 primary areas relevant to alcohol treatment studies: (i) trial registration, (ii) procedures for recruitment and retention, (iii) procedures for reporting on randomization and intervention design considerations, and (iv) the statistical methods used to assess treatment efficacy.
REPORTING GUIDELINES
The most influential approach to instituting reporting standards was developed by the CONSORT group in a statement first published in 1996 (Begg et al., 1996) and revised in 2001 Moher et al., 2001 ) and 2010 (Schulz et al., 2010) . The CONSORT statement is a description of critical reporting elements in clinical trials. It includes a diagram to summarize participant flow through an RCT and a checklist of 25 reportable trial design considerations that have been shown to influence the reliability and validity of treatment efficacy estimates. The CONSORT statement has been endorsed by 585 journals, many of which require the inclusion of the CONSORT diagram with all RCTs. The CONSORT diagram (http://www.consort-statement.org/ consort-statement/flow-diagram, last accessed March 22, 2015) summarizes participant flow, including enrollment, randomization, allocation, follow-up, and analysis in each of the intervention and control groups. The items in the CON-SORT checklist (http://www.consort-statement.org/consortstatement/checklist#/checklists/, last accessed March 22, 2015) cover various aspects of trial reporting, including the specific hypotheses tested, description of primary and secondary outcomes (i.e., end points), details on the method of randomization, effect sizes, and trial limitations. The widespread adoption and endorsement of the CONSORT guidelines have led to improvements in clinical trial reporting , but a systematic review of 16,604 RCTs concluded that many fail to follow the guidelines and suboptimal reporting of results is still a prevalent problem (Turner et al., 2012) .
Notably, because the CONSORT statement was developed for pharmacological studies, many aspects of it are less relevant for nonpharmacological treatments (e.g., because blinding of therapists and participants is not always possible in behavioral intervention research) and trials that involve patient-reported outcomes, both of which are relevant to RCTs for AUDs. To address these limitations, the CONSORT group extended and amended the guidelines for nonpharmacological treatments (Boutron et al., 2008) , including a modified participant flow diagram and the addition of an item that to detail the experimental and control treatments and how they are implemented. Other CONSORT extensions include guidelines for reporting RCTs in journal and conference abstracts (Hopewell et al., 2008a,b) and recommendations for describing patient-reported outcomes in RCTs (Calvert et al., 2013) .
COMPLIANCE WITH GUIDELINES IN ALCOHOL CLINICAL TRIALS
A systematic review and meta-analysis (Ladd et al., 2010 ) examined congruence with CONSORT reporting standards in 127 alcohol treatment RCTs. The authors found a significant improvement in the overall quality of reporting over time. However, Ladd and colleagues (2010) also found many CONSORT recommendations were followed in reports of <30% of studies, including the reporting of procedures used to identify the target sample size, method of randomization concealment, evidence for the success of the blinding procedure, stopping rules, details on protocol deviations, and identification of prognostic variables by treatment group. Many other critical aspects of trial design (e.g., the method used to generate the randomization schedule) and analyses (e.g., effect sizes for the intervention on primary and secondary outcomes) were reported by 60% or fewer of the studies reviewed.
Other recent studies have documented problems in the quality of reporting of alcohol treatment trial outcomes. A meta-analysis of pharmacotherapy for AUD delivered in outpatient settings (Jonas et al., 2014) included ratings of the potential risk of bias given the details provided in the original RCTs (including questions about randomization, blinding, attrition, validity and reliability of measures, whether intention-to-treat (ITT) analyses were used, fidelity, and missing data methods): Only 7 of 122 RCTs met criteria for "low" risk of bias as defined by independent raters. Similarly, Del Re and colleagues (2013) evaluated the analytic approaches of 165 alcohol pharmacotherapy trials and found that only 44.8% (74 trials) reported use of an ITT analytic strategy, often considered the "gold standard" method to analyze RCT data. Fewer than 40% of the studies that claimed to conduct ITT analyses actually conducted ITT analyses correctly, as called for by the CONSORT standards. In addition, the majority of trials did not report on which missing data strategy was used or relied on a demonstrably flawed method to handle missing data (mostly last observation carried forward; Hallgren and Witkiewitz, 2013) .
Based on these reviews, it is clear that the majority of alcohol clinical trials do not meet the reporting standards set forth by the CONSORT group. With these prior findings as the foundation, the remainder of this study will review selected reporting standards and empirical findings related to RCTs for alcohol and other substance use disorders. The primary goal of this review is to guide investigators, reviewers, and editors in improving the reporting of design features in alcohol treatment trials to facilitate the development of better treatments that can be made available to patients with AUDs.
TRIAL PREREGISTRATION AS A CRITICAL FIRST STEP
ClinicalTrials.gov is a repository for the registration and reporting of results from clinical trials in human participants. ClinicalTrials.gov was established to increase transparency in the design, conduct, analysis, and reporting of clinical trials, as required by Section 801 of the Food and Drug Administration Amendments Act (Public Law 110-95, 2007; Zarin and Tse, 2008) . The European Medicines Agency, the European Union, and the U.S. National Institutes of Health have also adopted the use of the registry.
As of December 2014, the ClinicalTrials.gov database included descriptions of 181,224 clinical trials being conducted in all 50 of the United States and in 187 countries. Of these registrations, 2,356 (1.3%) included individuals with AUDs or drinking level and/or AUD symptoms as the primary outcomes. This extensive database and preregistration will only meaningfully increase transparency to the extent that it impacts peer-reviewed studies and their reports. Currently, most editors and reviewers are not referencing the registry record in evaluating submitted manuscripts detailing RCT results (Mathieu et al., 2013) , and often, considerable discrepancies exist between the proposed analyses that were initially reported in the registries and the final analyses presented in published reports (Dwan et al., 2011) . Further, a review of the results from published trials that were registered in ClinicalTrials.gov suggests that most deviated from the preregistered plan of analysis in metric, method of aggregation, or timing of primary outcome measures employed, and the majority of studies (69%) failed to include all participants in the final published analyses (Zarin et al., 2011) . No study has explicitly examined discrepancies from trial registration in reporting alcohol treatment trials, but it is likely to be similarly problematic. It is imperative for trials to be preregistered, to follow the proposed protocol, and to report any deviations from the registry protocol in the published trial results.
REPORTING ON PROCEDURES FOR RECRUITMENT AND RETENTION
A discussion of all of the relevant procedures for recruitment and data collection is beyond the scope of the current review (see Witkiewitz et al., 2015) . A collection of articles in the July 2005 supplement to the Journal of Studies on Alcohol provides extensive coverage of issues related to recruitment and retention (Zweben et al., 2005) , developing an assessment battery for data collection (Gastfriend et al., 2005) , and coordinating and monitoring multisite studies (Youngblood et al., 2005) . Given prior extensive coverage of these topics, we focus here on 2 areas that have been problematic in prior reports of alcohol clinical trial findings: eligibility criteria and sample description, and participant retention.
Eligibility Criteria and Sample Description
Criteria for inclusion and exclusion must balance internal and external validity for a particular trial (Carroll and Rounsaville, 2003; Heather, 2014) . Seminal research by Humphreys et al. (Humphreys and Weisner, 2000; Humphreys et al., 2005 Humphreys et al., , 2008 has shown that most alcohol clinical trials apply extensive exclusion criteria that systematically oversample patients who are higher functioning, less ethnically and racially diverse, and more economically stable than those treated in clinical practice settings. For example, there is a tendency to exclude patients with psychiatric or other substance use comorbidity (Hoertel et al., 2014) and those with severe medical problems or unstable housing, all factors associated with a poorer prognosis in clinical settings (Humphreys et al., 2008) . Importantly, specific exclusion criteria predict either underestimation or overestimation of treatment effect sizes, and the direction and degree of underestimation or overestimation can vary across studies (Humphreys et al., 2008) . Given these findings, it is imperative that researchers carefully follow CONSORT guidelines in reporting all eligibility criteria, the rate at which potential participants are excluded from the final sample, and the basis for excluding potential participants.
Beyond describing the process by which participants were recruited, it is important that study reports clearly describe the sample's demographic and clinical characteristics. Investigators should report age, gender, race and ethnicity, weight and height or body mass index, education, employment status, marital status, the presence of comorbid psychiatric or drug use disorders, the severity and duration of AUD, and key baseline alcohol consumption measures. Other demographic and clinical characteristics relevant to the trial (e.g., concomitant medications, treatment history, housing status) may also need to be described. Reviews of alcohol treatment trials have shown that published reports are generally deficient in providing information on participants' demographic characteristics and history of alcohol misuse or disorders (e.g., Swearingen et al., 2003) . This information is critical in trying to evaluate the relative efficacy of different treatment approaches in research syntheses, as some participant populations may be more responsive to treatment ("easier to treat") than others.
Reporting on Study Retention
The CONSORT diagram provides clear instructions on how to present the number of individuals who prematurely discontinue the trial and those who complete it. It is particularly important to distinguish between patients who dropped out due to the treatment itself (e.g., those experiencing adverse events or no perceived treatment benefit), those who dropped out due to reasons potentially unrelated to the treatment (e.g., change in residence or employment status), and those who were lost to follow-up (i.e., did not respond to the researcher's prompts or reminders for assessment). Efforts made to increase retention should be described, as well as reasons for nonadherence (Zweben et al., 2005 (Zweben et al., , 2009 . There is also a CONSORT extension for reporting of the harms to patients in clinical trials (Ioannidis et al., 2004) . Reporting on adverse events is commonly lacking in nonpharmacological trials (Jonas et al., 2013) , but is essential in grading the evidence in terms of relative harms and benefits as part of systematic reviews. This information should be provided for all treatment conditions and at all assessment time points.
THE DESCRIPTION OF RANDOM ASSIGNMENT TO INTERVENTION OR COMPARATOR CONDITIONS, INTERVENTIONISTS, AND ASSESSMENT PROCEDURES

Procedures for Random Assignment
The RCT is often considered the gold standard to evaluate intervention efficacy, although the procedures used in randomization can jeopardize the validity of findings (Berger, 2006; Berger and Weinstein, 2004; Grossman and Mackenzie, 2005; Viera and Bangdiwala, 2007) . The CONSORT statement (Schulz et al., 2010) recommends that clinical trial reports include 4 aspects of randomization: the method used to generate the random allocation sequence (i.e., how the investigators ensured that patients have a known, not necessarily equal, probability of receiving each intervention before assignment and that the assignment is determined entirely by chance), the randomization type (e.g., blocked or stratified randomization), the allocation concealment method (i.e., the individuals enrolling patients have no knowledge of treatment assignment and are not allowed to accept or reject a patient based on treatment assignment), and how randomization was implemented, including who allocated, who enrolled, and who assigned participants to trial groups. In blinded treatment studies, the investigator should report whether the blind was broken and the circumstances that necessitated the unmasking of the blind (Haahr and Hr objartsson, 2006) .
Although numerous studies have examined biases resulting from inadequate randomization procedures across various types of clinical trials (Herbison et al., 2011; Savovi c et al., 2012; Schulz et al., 1995; Wood et al., 2008) , we were unable to locate any studies of randomization biases that might occur specifically in alcohol clinical trials. Future research should examine the degree and frequency with which alcohol clinical trials violate recommended randomization procedures and the effects of randomization bias on estimates of intervention efficacy.
Describing the Intervention and Study Procedures
The intervention is typically the primary focus of alcohol treatment trials, yet often little information is provided about the specific interventions tested. The CONSORT checklist clearly states that interventions, including control groups, should be described with "sufficient details to allow replication." For pharmacological interventions, this includes the drug name, dose, method of administration, titration procedures, and timing and duration of administration. The method for evaluating compliance with the medication, such as urinary riboflavin, medication event monitoring systems, or blister packs, also should be reported.
For nonpharmacological interventions, the CONSORT checklist includes additional recommendations for reporting the specific details of the experimental and comparator conditions, including a description of the components of the interventions and any tailoring of the interventions to individual participants, details regarding standardization of the interventions and adherence to the intervention protocols, and how adherence to intervention protocols was assessed. All of these recommendations can be particularly important in alcohol treatment trials in which "treatment as usual" or "standard care" interventions are included as comparison interventions (Brigham et al., 2009) , as these approaches may vary substantially across studies. This information is crucial to allow the relative effects of different interventions to be assessed in research syntheses.
It is also critical to report whether individual or group intervention delivery methods were utilized. If group interventions are used, the number of patients within each group and the potential impact of within-group effects on intervention outcomes should be reported. Although most trials have not shown a significant difference between group and individual intervention delivery methods (Graham et al., 1996; Marques and Formigoni, 2001; Sobell et al., 2009) , the cohesion within any 1 group of a trial could impact the overall intervention efficacy, so that the clustering of individuals within groups should be considered in the analyses (Greenfield et al., 2013) .
Describing the Interventionists and Treatment Fidelity
In both pharmacological and nonpharmacological interventions for AUDs, there is often substantial patient interaction with a therapist, nurse, or other healthcare professionals. The effects of such interventionists often explain a considerable amount of the variance in treatment outcomes (with estimates ranging from 3% to upward of 12%: Imel et al., 2008; Moyers and Miller, 2013) .
To help characterize the degree to which interactions with healthcare professionals might affect treatment outcomes, it is critical to report their training, the number of interactions they have with the patients, the average length of the meetings, and the content of those interactions including whether a prescribed intervention method was followed. This information also is critical for judging what would be required to implement the intervention in a real-world treatment setting, if it is shown to be efficacious.
In behavioral intervention trials, the interventionist can have a larger effect on the outcomes than the specific intervention being delivered (Miller and Moyers, 2015) ; thus, in addition to describing the interventionists' general training (e.g., degree, specialization), it is also important to report their training specific to the interventions being delivered in the trial for all conditions (Boutron et al., 2008) . Moreover, the number of interventionists within an intervention condition and the number of patients seen by each interventionist are important to report. Interventions that are delivered by a single interventionist are entirely confounded, making it impossible to determine whether the intervention or the interventionist is the active ingredient in treatment efficacy. Conversely, in situations in which multiple interventionists treat numerous patients, clustering of patients within interventionists is important to consider. In such cases, authors should report the intraclass correlation (ICC) for interventionist effects. The ICC provides a statistical index of the percent of outcome variance explained by clustering of individuals within a particular interventionist, where an ICC of 0 would indicate that outcomes are not explained by clustering within interventionist and an ICC closer to 1.0 would indicate that outcomes are largely correlated across individuals within interventionist. If the ICC suggests a considerable effect of therapists and the sample size of the trial is sufficiently large (note that the "sufficiency" of the sample size is based on numerous factors, as discussed by Hoyle and Gottfredson, in press), then ideally a mixed effects analysis would be reported, with interventionist included as a random effect, should be considered (for an example of this approach, see Lorentzen et al., 2013) . For studies with smaller samples or multiple interventionists with only 1 patient, the number of interventionists and the number of patients seen by each should be reported.
When using a manualized intervention or protocol, it is also important to report on the fidelity of the treatment delivery and competence of the interventionist in delivering the intended interventions (Miller et al., 2005) . Quantitative ratings of competence and adherence to the intervention (Carroll et al., 2000; Madson and Campbell, 2006) and whether there was ongoing interventionist monitoring and supervision should also be reported (Carroll and Rounsaville, 2007; Miller et al., 2005) .
Describing the Assessment Procedures
Research protocols, in and of themselves, can also exert effects, with reactivity to assessment significantly affecting engagement in alcohol treatment and outcomes Kaminer et al., 2008; Maisto et al., 2007) . Reactivity effects are likely to occur in the active intervention group and the control or placebo conditions, accounting for some improvement across groups and potentially obscuring between-group differences. Improvement across both groups may also be observed due to the phenomenon of regression to the mean (Finney, 2008) , which may occur for several reasons. One potential explanation for regression to the mean is the pretreatment or "baseline" assessment occurring when the participant's AUD symptoms and alcohol consumption have increased to the point of prompting him or her to seek treatment. A longer baseline assessment window (reporting retrospectively on the 90 days prior to baseline) could help to provide a better picture of the pretreatment drinking behavior (Gueorguieva et al., 2012; Stasiewicz et al., 2013) . Given prior findings on assessment reactivity and the effects of pretreatment drinking, it is critical to report such elements of the trial design as the length of time needed to complete assessments and the time periods covered by assessments.
REPORTING OF STATISTICAL METHODS TO ASSESS EFFICACY
Many statistical methods can be employed to assess intervention efficacy, with key determinants of validity being who was included in the analysis of outcomes (e.g., sample size and patient characteristics), which measures were analyzed, and how the analyses were conducted. Ideally, the statistical software syntax or programming code is included in supplementary materials, if allowed by the journal, and made available upon request by the corresponding author. Various programming tools can be used to enhance reproducibility without the need to share the trial data (Liu and Pounds, 2014) . We review the relevant reporting aspects of these features in the context of the CONSORT reporting guidelines with particular consideration given to the analysis of drinking outcomes in alcohol clinical trials.
Sample Size and Baseline Differences in Patient Characteristics
The CONSORT statement recommends that authors report the method for determining sample size, whether a priori power analyses were conducted to determine the sample size, or whether/why the actual sample size differs from the intended sample size. The CONSORT diagram shows the number of individuals screened, the number of participants allocated to treatment conditions, and the number of participants who completed the trials. The sample size at each step of participant flow through the trial should be well documented, with sample sizes and reasons for exclusion, and participant dropout from the intervention and/or research follow-up carefully tracked. To allow an evaluation of the efficacy of the intervention, it is critically important to report whether there are differences in baseline characteristics or attrition rates between intervention groups.
Reporting in Multisite Studies
Many alcohol clinical trials are conducted across multiple sites (often in different states) or multiple treatment programs within a particular research site (Anton et al., 2006; Project MATCH Research Group, 1997) . It is important to report the number of sites and the size of the sample within each site because in multisite trials both can influence the power to detect treatment effects (Feaster et al., 2011) . The COMBINE study, the largest multisite alcohol pharmacotherapy trial conducted in the United States to date, included 1,383 alcohol-dependent individuals recruited from alcohol treatment programs by 11 research teams across the United States. Because nearly all analyses indicated significant site effects, the investigators controlled for site in the primary outcome analyses (Anton et al., 2006) .
A discussion of statistical methods that can be used effectively to control for site differences is beyond the scope of this review (see Witkiewitz et al., 2015) . However, at the very least, authors should provide the reader with an indication of whether site effects were detected and how site was included in the analyses. To quantify site effects on the primary outcome measures, investigators can calculate the ICC (Desai and Begg, 2008) . Importantly, as the ICC gets larger, so does the number of participants needed to detect a given effect size. Reporting of ICC (whether at the level of the site, group, or therapist, as described above) is valuable to inform power estimates in subsequent studies. Graphical depictions of site effects, including simple forest plots of the confidence intervals (CIs) of the treatment effects for each site, are also helpful.
Outcome Measure Description
CONSORT standards require clearly defined primary and secondary outcome measures and, when applicable, a description of any methods used to enhance the quality of measurements (e.g., multiple observations, training of assessors). The standards also require specification of the primary time point for evaluating efficacy (e.g., end of active treatment intervention vs. a more remote follow-up assessment). The reporting of primary and secondary outcomes should be consistent with the analysis plan, as stated in the trial registration.
In most alcohol treatment studies, the primary and/or secondary outcome measures are likely to be based on alcohol consumption, often assessed via self-report. The current "gold standard" method to obtain self-reported alcohol consumption data is via a calendar method such as the timeline follow-back method (Sobell and Sobell, 1992) or Form-90 (Miller, 1996) . These methods provide estimates of daily alcohol consumption in a preselected standard drink unit and can yield reliable and valid estimates of alcohol consumption via a variety of assessment modalities (e.g., online, mobile, phone) in numerous studies (e.g., Bernhardt et al., 2009; Pedersen et al., 2012; Sobell et al., 1996) .
Estimated alcohol consumption at the daily level is often aggregated to provide various estimates of drinking outcomes, such as percentage of days abstinent, drinks per drinking day, heavy drinking days (where "heavy" drinking is defined as 4 or more drinks for women and 5 or more drinks for men), or drinks per day (Anton et al., 2006; Project MATCH Research Group, 1997) .
Investigators should report the standard drink unit size and the method of aggregation. The National Institute on Alcohol Abuse and Alcoholism has recommended that the primary measure be heavy drinking, with the percentage of individuals with no heavy drinking days as the primary end point in alcohol clinical trials (Falk et al., 2010; Sobell et al., 2003) . A binary measure of no heavy drinking has been proposed as a primary end point in the Food and Drug Administration's draft guidance for AUD medications development (Food and Drug Administration, 2015) , and the European Medicines Agency (2010) has approved reductions in heavy drinking as a primary end point for trials with harm reduction goals. Yet, there is still a lack of consensus among researchers in the field regarding the optimal outcome for treatment studies, and the selection of primary and secondary outcomes can depend on the goal of the trial . We recommend that, when alcohol consumption is used as an outcome, information is provided on the use of biomarkers of alcohol use, which are commonly used to validate self-report data, along with the correspondence between the biomarker(s) and self-reported consumption measures . Evidence of efficacy for an intervention that is consistent across self-report measures and biomarker findings adds substantially to the validity of the findings.
When reporting on any measures used in a trial, an assessment of the reliability and validity of the measures is also warranted. Importantly, measures are not inherently reliable or valid (Vacha-Haase, 1998); rather, reliability and validity pertain to a particular administration of a measure. Thus, investigators should report any potential threats to the reliability or assessment validity of the measures in a given study (e.g., whether results were exclusively for research or became part of the medical record), as well as the internal consistency reliability coefficients of the measures from the study sample.
Presentation of Data and Statistical Analyses
Various statistical analyses can be appropriate to identify intervention effects in alcohol clinical trials. However, instead of discussing specific approaches (see Witkiewitz et al., 2015) , we provide general recommendations for reporting of results and encourage authors to follow the CONSORT recommendation to describe all analyses in enough detail to permit the results to be replicated by a knowledgeable reader who obtains the original data sets.
(1) Means and standard deviations or frequencies of primary outcomes, and sample sizes, for each intervention group at each assessment point should be provided. Reporting these features allows for the estimation of effect sizes that can guide future research and indicates whether key variables are normally distributed. The distribution of alcohol treatment outcome measures is often skewed, with a preponderance of zero values (e.g., drinking days among abstainers), which can bias statistical tests that assume a normal distribution. Methods to transform outcome data to achieve a more normal distribution should be reported.
(2) Primary analyses and any exploratory analyses should be clearly described and as prespecified in the clinical trial registry. In the Abstract and the Results section, authors should report the estimate of the intervention effect (defined as the difference on the primary outcome measure between intervention and comparison groups), as well as the effect size and its 95% CI (Kelley and Preacher, 2012) . Any deviations from the primary outcome analyses specified in the clinical trial registry should be clearly indicated (Hartung et al., 2014) . Importantly, the predefined alpha should be reported and results that do not meet that level of significance (e.g., p = 0.07) should not be interpreted as "trend" level effects. The number needed to treat, defined as the number of patients that must be treated to prevent 1 additional negative outcome (e.g., heavy drinking day) or achieve 1 additional positive outcome (e.g., an abstinent day), and success rate (defined as the probability that an intervention patient compared to a control patient has the intended outcome) are recommended measures of effect size (Kraemer and Kupfer, 2006) and should also be reported with their 95% CI.
For most RCTs, the primary analysis should be based on the original allocation of participants to intervention conditions, such that all individuals initially allocated to an intervention group are included in the analyses as members of that group (i.e., an ITT analysis). As noted earlier, this principle has been compromised in some alcohol clinical trials by the use of a "modified" ITT approach or an incorrectly implemented ITT approach (Del Re et al., 2013) . It is critical for the authors to report the type of analyses that were conducted with regard to randomization and how allocation was preserved (or not) in the primary analysis of intervention effects. Exploratory analyses, particularly subgroup and adjusted analyses, should be clearly specified. Ideally, exploratory analyses are planned a priori based on prior research or theoretical considerations and reflected in the trial registration. Post hoc analyses (i.e., those proposed after examining the collected data) may lead to spurious findings that are less likely to be replicated (Freemantle, 2001; Pocock et al., 1987) . Such findings, when reported, should be identified as having been proposed after data collection.
(3) Attrition and methods for handling missing data should be reported. Missing data are, unfortunately, quite common in alcohol treatment trials. Although much has been learned about the factors that contribute to patient dropout from drug and alcohol treatment (Ball et al., 2006; Brorson et al., 2013; Coulson et al., 2009; Palmer et al., 2009) , oftentimes the reasons for missing data in both clinical care and clinical trials are unknown. Attrition by treatment group, time point, and site (if the study is a multisite trial) should be reported. Any systematic differences in attrition rates (e.g., more attrition among females, or among older patients) should also be reported, and variables associated with attrition should be considered as covariates in subsequent analyses (National Research Council, 2010 ). In addition, the level of adherence to the medication and the methods used to evaluate medication adherence, as well as attendance at behavioral treatment sessions, should be reported, with consideration given to their use as covariates (Baros et al., 2007; Stout et al., 2014; Swift et al., 2011) .
Regardless of the reasons for attrition, it is critically important to report the method used to address missing data in the analysis of the primary and secondary outcomes. In their review, Del Re and colleagues (2013) found that 23% of alcohol clinical trials did not provide sufficient information to verify the missing data procedure that was used in the analysis of the primary outcome. Of studies that reported the missing data procedure used, complete case analysis, assuming failure (i.e., heavy drinking), and last observation carried forward were the most commonly used approaches (Del Re et al., 2013) . Two recent studies of different approaches to handling missing data in alcohol clinical trials, one of which use simulation based on the COMBINE study data (Hallgren and Witkiewitz, 2013) and the other of which used the actual COMBINE study data (Witkiewitz et al., 2014) , showed that these approaches produced the most biased estimates of treatment effects, while maximum likelihood estimation and multiple imputation approaches provided the least biased estimates of treatment effects.
Researchers should specify a plan for handling missing data at the time of clinical trial registration. They should then report the method used to handle missing data, acknowledging any variation from the prespecified plan, which should be based on consultation with the most recent statistical literature to identify the least biased methods to estimate treatment effects in the presence of missing data.
CONCLUSIONS AND FUTURE DIRECTIONS
Despite the high prevalence and substantial public health impact of AUDs in both the United States and globally, there are relatively few efficacious treatments for AUDs (Jonas et al., 2014; Magill and Ray, 2009; National Institute for Health and Care Excellence, 2011; Vasilaki et al., 2006; Zindel and Kranzler, 2014) . Given these findings, it is critical that researchers continue to develop, evaluate, and disseminate efficacious treatments for AUDs. A major barrier to the evaluation and dissemination of effective treatments is the lack of appropriate reporting of study features from alcohol treatment trials. Notably, the potential risks of bias have been shown to artificially inflate treatment effect sizes in AUD research (Jonas et al., 2014; Ladd et al., 2010) , which ultimately could impede dissemination efforts when medications or behavioral interventions prove less effective in real-world settings (Humphreys and Weisner, 2000) . Only with more complete and transparent reporting can potential biases in alcohol treatment trials be gauged.
Although the CONSORT statement and its extensions (Boutron et al., 2008; Calvert et al., 2013; Schulz et al., 2011) have generally improved reporting practices for RCTs, much improvement is still needed in trial reporting for all diseases (Turner et al., 2012) , including AUDs (Ladd et al., 2010) . We have highlighted several areas of particular relevance to AUD RCTs, including eligibility criteria, retention of participants, procedures for random assignment, descriptions of the interventions and interventionists, and several considerations in the reporting of statistical analyses consistent with trial registration. These recommendations for reporting after trial completion are included as a checklist in Table 1 . Trial registration and careful documentation of any discrepancies between the analyses planned a priori and the completed primary or secondary outcome analyses are critical to evaluate the validity of trial findings and whether post hoc explanations or "fishing expeditions" account for the apparent efficacy of the treatment, although sometimes these explorations lead to a new insight that requires replication. Journal editors and reviewers are often aware of deficits in clinical trial methodology (Harris et al., 2009 ), but are often unaware of discrepancies that exist between reported study methods and those in the planned protocol in the trial registry (Dwan et al., 2011; Mathieu et al., 2013) . Authors could be required to provide a copy of the trial registration with submitted manuscripts, which would provide journal editors and reviewers with the opportunity to evaluate departures from the a priori analyses that reflect "cherry-picking" results for publication purposes (Zarin et al., 2011) .
We conclude that poor reporting practices and deviations from planned preregistered protocols for evaluating treatments for AUDs (especially unreported deviations) impede the application of the scientific method to the development of efficacious AUD treatments and degrade the evidence base needed to optimize systematic reviews. We recognize that journal page limits often restrict the amount of information that can be reported. Many journals now allow supplementary materials to be published online and using this outlet to incorporate all recommended reporting elements (both the CONSORT and the recommendations in Table 1) should be considered. We also encourage all researchers, journal editors, and reviewers to work to ensure careful reporting practices so that published trial reports contribute meaningfully to the cumulative science of evidence-based treatments for AUDs.
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This research was supported by grants from the National Institute on Alcohol Abuse and Alcoholism (AA022328 to Abstract-Description of trial design, participants (including sample size and demographics), main findings (including effect sizes and/or 95% confidence intervals), and conclusions from the study Introduction-Description of background for the study, why the current study is necessary in the context of existing research, and the specific objectives and hypotheses of the current study Methods-Participants Participant selection procedures, how sample size was determined, and setting of recruitment reported Detailed description of inclusion and exclusion criteria, rationale for inclusion and exclusion criteria, and the numbers excluded and reasons for exclusion in the sample Participant demographic and clinical characteristics reported, for entire sample and by intervention groups. Differences in demographic or clinical characteristics across intervention groups reported Provide CONSORT flow diagram to characterize retention in the study and reasons for dropping out Report numbers experiencing adverse events and type and severity of adverse events Methods-Randomization Follow CONSORT guidance for reporting on method used to generate the randomization sequence, the type of randomization, the allocation concealment method, and randomization implementation methods If study is blinded, then report of who was blinded and if and when the blind was broken Methods-Descriptions of Interventions and Procedures For pharmacological interventions, report the drug name, dose, method of administration, titration procedures, timing and duration of administration, and adherence monitoring methods For nonpharmacological interventions, report specific details of the experimental and comparator conditions, including a description of type and format of intervention, and details regarding standardization of the interventions and adherence to the intervention protocols For all trial types, describe the degree and type of interactions with any health professionals related to the trial, including number of interventionists, training of interventionists, and number of patients seen by each interventionist. Report ICCs primary and secondary outcomes by interventionist Describe the assessment procedures, including duration, timing, and location of all research assessments In multisite studies, provide a description of the number of sites and characteristics of sites, indicate whether site effects were detected and how site was included in analyses. Report ICCs for primary and secondary outcomes by site Define primary and secondary outcomes, methods used to enhance quality of outcome assessment, and time points at which outcomes were assessed. Outcome selection is based on the trial registration Reliability and validity of assessment of primary and secondary outcomes reported Methods and Results-Statistical Analyses Means and standard deviations or frequencies of primary and secondary outcomes, and sample sizes, for each intervention group at each assessment point reported Primary analyses and any exploratory analyses clearly described and as prespecified in the clinical trial registry. Any deviations from the primary outcome analyses specified in the clinical trial registry clearly described. If randomized design report how allocation was preserved in the primary analysis Report the estimate of the intervention effect (defined as the difference on the primary outcome measure between intervention and comparison groups), as well as the effect size and its 95% confidence interval Clearly describe attrition and methods for handling missing data.
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